Category: Gastrointestinal

Categories : Gastrointestinal Neurodegenerative DiseasesTags :

Gut Immune Cells Protect The Brain in MS Flare-ups

On By ModernMedia

Scientists from the University of California, San Francisco, have observed gut immune cells moving up out of the gastrointestinal tract to the brain during multiple sclerosis (MS) flareups, where they seem to exert some protective effects.

In MS, other immune cells attack the myelin sheath, resulting in flare-ups, where they experience memory problems, vision loss, pain and other problems. These flare-ups subside after some days, but it is not known why the disease switches back and forth between flare-up and remission.

The new research revealed that the flare-ups were brought under control with the unlikely assistance of gut immune cells, which produce Immunoglobulin-A (IgA) and act as the immune system’s first line of defence in the GI tract. Some of these cells actually leave the gut and migrate to the brain, where it appears they reduce inflammation.

“It was a very new idea,” said lead author, Sergio Baranzini, PhD, neurology professor at the UCSF Weill Institute for Neurosciences, . “Nobody thought to look for this type of immune cell.”

The gut immune cells were found only in cerebrospinal fluid of MS sufferers when they experienced a flare-up, and not in remission. Recent research indicated that an unhealthy GI microbiome was involved in MS, and the researchers determined that these immune cells only attacked potentially damaging bacteria, not the myelin sheath.

It is anticipated that this discovery may bring insights into new therapies to treat the disease. 

Source: Medical Xpress

Categories : Diseases, Syndromes and Conditions Gastrointestinal PulmonologyTags :

Gut Microbiome is Linked to Pulmonary Disease

On By ModernMedia

A link has been shown between the gut microbiome and chronic obstructive pulmonary disease (COPD), a lung disease with an often poor prognosis.

Senior author Prof Phil Hansbro, Director of the Centenary University of Technology Sydney Centre for Inflammation, said, “It’s already known that the lung microbiome is a contributing factor in COPD. We wanted to see if the gut environment was also somehow involved–to determine whether the gut could act as a reliable indicator of COPD or if it was connected in some way to the development of the disease.”

Stool samples of COPD patients showed elevated levels of the bacteria Streptococcus and Lachnospiraceae. Additionally a unique metabolite signature was identified in individuals with COPD, created by the chemical by-products of the metabolic process.

First author Dr Kate Bowerman from the University of Queensland said, “Our research indicates that the gut of COPD patients is notably different from healthy individuals. This suggests that stool sampling and analysis could be used to non-invasively diagnose and monitor for COPD,” she said.
“The ‘gut-lung axis’ describes the common immune system of the lung and gastrointestinal tract. This means that activity in the gut can impact activity in the lung. Our COPD findings suggest that the gut microbiome should now also be considered when looking for new therapeutic targets to help treat lung disease,” Prof Hansbro said.

Source: Medical Xpress